HIV transmission risk behaviors are common and recalcitrant among persons with methamphetamine (METH) dependence, but their underlying cognitive and neurobiological mechanisms are not well understood. During the previous funding period we learned that METH dependence may differentially impact the expression of inhibitory deficits related to risk taking in the setting of HIV infection in humans and mouse models. Building on this work, the current application requests support for parallel human and animal research to determine the individual and combined effects of METH dependence, HIV infection and aging on risk taking. We will leverage our expertise in implementing cross-species measures by evaluating several important components of risk taking that will be isolated paradigmatically in humans and two mouse models of HIV: 1) Preference for risk, reward and/or novelty versus punishment avoidance, 2) motivation defined as willingness to work for a reward, and 3) inhibition. In the human study, we will test our hypothesis HIV and METH have differentiable effects on the multiple components that underlie risk taking in all 320 well-characterized subjects from the TMARC cohort that will be stratified by METH dependence, HIV serostatus, and age. We will also examine the impact of aging on the expression of risk behaviors in HIV and METH, as well as the unique effects of risk taking and its components on real-world outcomes (e.g., adherence) in our clinical groups. Shared human subjects with TMARC Project 2 will allow us to examine the neural substrates of risky decision-making, including neuroimaging indices of functional connectivity and white matter injury. The animal studies will employ two mouse models of HIV (i.e., constitutive gp120tg and conditional iTat-tg) with and without METH treatment that will be evaluated with cognitive paradigms that map directly on to those used with our human subjects. Collaborations with the TMARC Neuroimaging and Neuroscience and Animal Models Cores will us to parse out biological mechanisms of these critical cognitive functions in mouse models. The ultimate goal of this research is to propel the design prevention efforts that target specific components of risk taking in order to reduce HIV transmission.
Risk taking behavior is common in persons with HIV and methamphetamine dependence. The ultimate goal of this cross-species study of humans and mice is to facilitate the design of treatment and prevention efforts that target the specific cognitive components of risk taking in HIV and methamphetamine in order to reduce HIV transmission.
|Morgan, Erin E; Iudicello, Jennifer E; Cattie, Jordan E et al. (2015) Neurocognitive impairment is associated with lower health literacy among persons living with HIV infection. AIDS Behav 19:166-77|
|Casaletto, K B; Obermeit, L; Morgan, E E et al. (2015) Depression and executive dysfunction contribute to a metamemory deficit among individuals with methamphetamine use disorders. Addict Behav 40:45-50|
|Maung, Ricky; Hoefer, Melanie M; Sanchez, Ana B et al. (2014) CCR5 knockout prevents neuronal injury and behavioral impairment induced in a transgenic mouse model by a CXCR4-using HIV-1 glycoprotein 120. J Immunol 193:1895-910|
|Morgan, Erin E; Doyle, Katie L; Minassian, Arpi et al. (2014) Elevated intraindividual variability in methamphetamine dependence is associated with poorer everyday functioning. Psychiatry Res 220:527-34|
|Kamat, Rujvi; Brown, Gregory G; Bolden, Khalima et al. (2014) Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection. J Clin Exp Neuropsychol 36:854-66|
|Montoya, Jessica L; Georges, Shereen; Poquette, Amelia et al. (2014) Refining a personalized mHealth intervention to promote medication adherence among HIV+ methamphetamine users. AIDS Care 26:1477-81|
|Desplats, Paula; Dumaop, Wilmar; Cronin, Peter et al. (2014) Epigenetic alterations in the brain associated with HIV-1 infection and methamphetamine dependence. PLoS One 9:e102555|
|Henry, Brook L; Geyer, Mark A; Buell, Mahalah R et al. (2014) Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav Pharmacol 25:12-22|
|Tatro, Erick T; Purnajo, Intan; Richman, Douglas D et al. (2014) Antibody response to Achromobacter xylosoxidans during HIV infection is associated with lower CD4 levels and increased lymphocyte activation. Clin Vaccine Immunol 21:46-50|
|Iudicello, Jennifer E; Morgan, Erin E; Gongvatana, Assawin et al. (2014) Detrimental impact of remote methamphetamine dependence on neurocognitive and everyday functioning in older but not younger HIV+ adults: evidence for a legacy effect? J Neurovirol 20:85-98|
Showing the most recent 10 out of 44 publications